CLARITROMICINA (KLACID) ÎN TERAPIA ANTIBACTERIANĂ

October 1, 1997

Em. Manolescu *, Camelia Vreto **
* Prof. dr. Emanoil Manolescu, Catedra de Farmacologie, UMF Carol Davila, București
** Dr. Camelia Vreto, medic primar pediatrie – Constanța

Abstract

Claritromicine is a new macrolide, presenting advantages compared to erythromicine in terms of pharmacokinetics, broad antibacterial spectrum and reduced secundary effects. Therefore it has a rapid, complete digestive absorbtion uninfluenced by food, prolonged active plasma levels and greater tissular than plasma concentrations. The antibacterial spectrum is broader and it is especially active in respiratory and ENT infections with Legionella, Chlamydia and Mycobacterium avium. The secondary effects are uncommon and without clinical relevance.

Previous Story

MEDICAȚIA ADMINISTRATĂ INHALATOR ÎN TRATAMENTUL BRONHOPNEUMOPATIEI OBSTRUCTIVE CRONICE – ACTUALITĂȚI

Next Story

EFICACITATEA CLARITROMICINEI COMPARATIV CU A RITROMICINEI ÎN TRATAMENTUL INFECȚIILOR BRONHOPULMONARE CU MYCOPLASMA PNEUMONIAE